Advances in clinical pharmacotherapy for neonatal Ureaplasma urealyticum infection

Bei-Bo CAI; Fei-Fei CHEN; Fang LUO

doi:10.7499/j.issn.1008-8830.2503019

PDF(598 KB)

Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (10) : 1286-1290. DOI: 10.7499/j.issn.1008-8830.2503019

REVIEW

Advances in clinical pharmacotherapy for neonatal Ureaplasma urealyticum infection

Author information +

History +

Abstract

Ureaplasma urealyticum (UU) is a common pathogen colonizing or infecting the neonatal respiratory tract. It can be vertically transmitted from mother to infant, irrespective of the duration of premature rupture of membranes and the mode of delivery. UU infection is an important factor contributing to preterm birth and low birth weight and is closely associated with adverse outcomes such as bronchopulmonary dysplasia and neurodevelopmental impairment. Given the immaturity of neonatal immune and organ systems, pharmacologic treatment must balance efficacy and safety. Currently, no unified standard regimen has been established for the treatment of neonatal UU infection. This review summarizes pharmacotherapeutic options for neonatal UU infection to inform clinical practice.

Key words

Ureaplasma urealyticum / Therapy / Macrolides / Neonate

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Bei-Bo CAI , Fei-Fei CHEN , Fang LUO. Advances in clinical pharmacotherapy for neonatal Ureaplasma urealyticum infection[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(10): 1286-1290 https://doi.org/10.7499/j.issn.1008-8830.2503019

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]

Tadera

, Kitagawa

, Kitano

, et al. Prevalence of Mycoplasma hominis, Ureaplasma urealyticum, and Ureaplasma parvum detection in urine and respiratory tract samples in Hiroshima, Japan[J]. Heliyon, 2023, 9(3): e14543. PMCID: PMC10036642. DOI: 10.1016/j.heliyon.2023.e14543 .

https://www.ncbi.nlm.nih.gov/pubmed/36967949

Cited in this article [1]

[2]	石永言, 富建华. 解脲脲原体感染与新生儿疾病[J]. 中华实用儿科临床杂志, 2021, 36(14): 1059-1062. DOI: 10.3760/cma.j.cn101070-20201222-01929 . Cited in this article [1]

[3]	Ma J, Wang Z, Luo C, et al. Epidemiological and clinical characteristics of neonatal Ureaplasma urealyticum infection[J]. Infect Drug Resist, 2024, 17: 1323-1332. PMCID: PMC10995099. DOI: 10.2147/IDR.S452014 . https://www.ncbi.nlm.nih.gov/pubmed/38585416 Cited in this article [1]

[4]	Silwedel C, Laube M, Speer CP, et al. The role of Ureaplasma species in prenatal and postnatal morbidity of preterm infants: current concepts[J]. Neonatology, 2024, 121(5): 627-635. DOI: 10.1159/000539613 . https://www.ncbi.nlm.nih.gov/pubmed/38934167 Cited in this article [1]

[5]	魏红玲, 邢燕, 周颖, 等. 胎龄小于32周早产儿解脲脲原体肺炎的临床特征分析[J]. 中华预防医学杂志, 2021, 55(2): 239-244. DOI: 10.3760/cma.j.cn112150-20201208-01432 . https://www.ncbi.nlm.nih.gov/pubmed/34645186 Cited in this article [1]

[6]	郑淮武, 万胜明, 邱素清. 解脲支原体与新生儿疾病关系的研究进展[J]. 中华新生儿科杂志（中英文）, 2019, 34(3): 234-238. DOI: 10.3760/cma.j.issn.2096-2932.2019.03.019 . Cited in this article [2]

[7]

Jonduo

, Vallely

, Wand

, et al. Adverse pregnancy and birth outcomes associated with Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum: a systematic review and meta-analysis[J]. BMJ Open, 2022, 12(8): e062990. PMCID: PMC9422885. DOI: 10.1136/bmjopen-2022-062990 .

https://www.ncbi.nlm.nih.gov/pubmed/36028274

Cited in this article [1]

[8]	陈凌, 汤颖, 杨羡球. 解脲脲原体感染新生儿血常规、D-二聚体及降钙素原水平与坏死性小肠结肠炎的关系研究[J]. 中国现代医学杂志, 2024, 34(15): 7-12. DOI: 10.3969/j.issn.1005-8982.2024.15.002 .

[9]	Sprong KE, Mabenge M, Wright CA, et al. Ureaplasma species and preterm birth: current perspectives[J]. Crit Rev Microbiol, 2020, 46(2): 169-181. DOI: 10.1080/1040841X.2020.1736986 . https://www.ncbi.nlm.nih.gov/pubmed/32141797

[10]

Silwedel

, Schnee

, Liese

, et al. Neonatal central nervous system infection by Ureaplasma species is rare, but relevant: results from a multicenter nationwide surveillance study[J]. Infection, 2025, 53(4): 1329-1339. PMCID: PMC12316750. DOI: 10.1007/s15010-024-02435-2 .

https://www.ncbi.nlm.nih.gov/pubmed/39821739

[11]	王燕琼, 曾雅丽, 陈雪雨, 等. 超早产儿解脲脲原体感染及定植状态的临床特征分析[J]. 中国当代儿科杂志, 2024, 26(8): 811-816. PMCID: PMC11334552. DOI: 10.7499/j.issn.1008-8830.2403002 . https://www.ncbi.nlm.nih.gov/pubmed/39148384

[12]	Sun T, Fu J. Analysis of the clinical features of intrauterine Ureaplasma urealyticum infection in preterm infants: a case-control study[J]. Front Pediatr, 2021, 9: 774150. PMCID: PMC8696116. DOI: 10.3389/fped.2021.774150 . https://www.ncbi.nlm.nih.gov/pubmed/34956983 Cited in this article [1]

[13]	Pansieri C, Pandolfini C, Elie V, et al. Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey[J]. Sci Rep, 2014, 4: 4076. PMCID: PMC5379254. DOI: 10.1038/srep04076 . https://www.ncbi.nlm.nih.gov/pubmed/24518104 Cited in this article [1]

[14]

Samra

, Rosenberg

, Dan

. Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin[J]. J Chemother, 2011, 23(2): 77-79. DOI: 10.1179/joc.2011.23.2.77 .

https://www.ncbi.nlm.nih.gov/pubmed/21571622

Cited in this article [4]

[15]	胡海燕. 新生儿呼吸道解脲支原体的感染情况与药敏分析[J]. 中国卫生检验杂志, 2021, 31(2): 165-167. Cited in this article [1]

[16]

Mabanta

, Pryhuber

, Weinberg

, et al. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum [J]. Cochrane Database Syst Rev, 2003(4): CD003744. DOI: 10.1002/14651858.CD003744 .

https://www.ncbi.nlm.nih.gov/pubmed/14583992

Cited in this article [1]

[17]

Resch

, Gutmann

, Reiterer

, et al. Neonatal Ureaplasma urealyticum colonization increases pulmonary and cerebral morbidity despite treatment with macrolide antibiotics[J]. Infection, 2016, 44(3): 323-327. DOI: 10.1007/s15010-015-0858-7 .

https://www.ncbi.nlm.nih.gov/pubmed/26518581

Cited in this article [1]

[18]

Abdellatif

, Ghozy

, Kamel

, et al. Association between exposure to macrolides and the development of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis[J]. Eur J Pediatr, 2019, 178(3): 301-314. DOI: 10.1007/s00431-018-3287-7 .

https://www.ncbi.nlm.nih.gov/pubmed/30470884

Cited in this article [1]

[19]

Cakan

, Polat

, Kocazeybek

, et al. Assessment of antibiotic susceptibility of Ureaplasma urealyticum from prostitutes and outpatient clinic patients using the E-test and agar dilution method[J]. Chemotherapy, 2003, 49(1/2): 39-43. DOI: 10.1159/000069781 .

https://www.ncbi.nlm.nih.gov/pubmed/12714809

Cited in this article [1]

[20]

Viscardi

, Terrin

, Magder

, et al. Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants[J]. Arch Dis Child Fetal Neonatal Ed, 2020, 105(6): 615-622. PMCID: PMC7592356. DOI: 10.1136/archdischild-2019-318122 .

https://www.ncbi.nlm.nih.gov/pubmed/32170033

Cited in this article [1]

[21]

Viscardi

, Terrin

, Magder

, et al. Randomized trial of azithromycin to eradicate Ureaplasma respiratory colonization in preterm infants: 2-year outcomes[J]. Pediatr Res, 2022, 91(1): 178-187. PMCID: PMC8413397. DOI: 10.1038/s41390-021-01437-2 .

https://www.ncbi.nlm.nih.gov/pubmed/33658655

Cited in this article [1]

[22]

Ballard

, Anstead

, Shook

. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study[J]. Respir Res, 2007, 8(1): 41. PMCID: PMC1896160. DOI: 10.1186/1465-9921-8-41 .

https://www.ncbi.nlm.nih.gov/pubmed/17550598

Cited in this article [1]

[23]

Ballard

, Shook

, Bernard

, et al. Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial[J]. Pediatr Pulmonol, 2011, 46(2): 111-118. DOI: 10.1002/ppul.21352 .

https://www.ncbi.nlm.nih.gov/pubmed/20963840

Cited in this article [1]

[24]	Gharehbaghi MM, Peirovifar A, Ghojazadeh M, et al. Efficacy of azithromycin for prevention of bronchopulmonary dysplasia (BPD)[J]. Turk J Med Sci, 2012, 42(6): 1070-1075. DOI: 10.3906/sag-1107-18 . Cited in this article [1]

[25]

Nunes

, Procianoy

, Corso

, et al. Use of azithromycin for the prevention of lung injury in mechanically ventilated preterm neonates: a randomized controlled trial[J]. Neonatology, 2020, 117(4): 522-528. DOI: 10.1159/000509462 .

https://www.ncbi.nlm.nih.gov/pubmed/32894857

Cited in this article [1]

[26]	Zeng Y, Huang Z, Wang Y, et al. Azithromycin for preventing bronchopulmonary dysplasia in extremely preterm infants: a cohort study[J]. Pediatr Pulmonol, 2025, 60(1): e27384. PMCID: PMC11758769. DOI: 10.1002/ppul.27384 . https://www.ncbi.nlm.nih.gov/pubmed/39503175 Cited in this article [1]

[27]

Chen

, Huang

, Lin

, et al. Association of Ureaplasma infection pattern and azithromycin treatment effect with bronchopulmonary dysplasia in Ureaplasma positive infants: a cohort study[J]. BMC Pulm Med, 2023, 23(1): 229. PMCID: PMC10294412. DOI: 10.1186/s12890-023-02522-4 .

https://www.ncbi.nlm.nih.gov/pubmed/37365524

Cited in this article [1]

[28]	张艳, 宋晓彤, 徐思媛, 等. 红霉素与阿奇霉素治疗早产儿解脲脲原体感染的随机对照研究[J]. 中华新生儿科杂志（中英文）, 2024, 39(12): 723-728. DOI: 10.3760/cma.j.issn.2096-2932.2024.12.004 . Cited in this article [1]

[29]	Razak A, Alshehri N. Azithromycin for preventing bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis[J]. Pediatr Pulmonol, 2021, 56(5): 957-966. DOI: 10.1002/ppul.25230 . https://www.ncbi.nlm.nih.gov/pubmed/33382534 Cited in this article [1]

[30]

Chang

, Ballard

, Johnson

, et al. Azithromycin for eradication of Ureaplasma and prevention of bronchopulmonary dysplasia in preterm neonates in the neonatal intensive care unit[J]. J Pediatr Pharmacol Ther, 2023, 28(1): 10-19. PMCID: PMC9901312. DOI: 10.5863/1551-6776-28.1.10 .

https://www.ncbi.nlm.nih.gov/pubmed/36777984

Cited in this article [1]

[31]	Smith C, Egunsola O, Choonara I, et al. Use and safety of azithromycin in neonates: a systematic review[J]. BMJ Open, 2015, 5(12): e008194. PMCID: PMC4679913. DOI: 10.1136/bmjopen-2015-008194 . https://www.ncbi.nlm.nih.gov/pubmed/26656010 Cited in this article [1]

[32]	Ozdemir R, Erdeve O, Dizdar EA, et al. Clarithromycin in preventing bronchopulmonary dysplasia in Ureaplasma urealyticum-positive preterm infants[J]. Pediatrics, 2011, 128(6): e1496-e1501. DOI: 10.1542/peds.2011-1350 . https://www.ncbi.nlm.nih.gov/pubmed/22123897 Cited in this article [1]

[33]	Guo D, Cai Y, Chai D, et al. The cardiotoxicity of macrolides: a systematic review[J]. Pharmazie, 2010, 65(9): 631-640. https://www.ncbi.nlm.nih.gov/pubmed/21038838 Cited in this article [1]

[34]

Pereyre

, Hénin

, Dolzy

, et al. Evaluation of commercial, customized microdilution plates for Ureaplasma parvum, Ureaplasma urealyticum, and Mycoplasma hominis antimicrobial susceptibility testing and determination of antimicrobial resistance prevalence in France[J]. J Clin Microbiol, 2024, 62(7): e0022624. PMCID: PMC11324033. DOI: 10.1128/jcm.00226-24 .

https://www.ncbi.nlm.nih.gov/pubmed/38832769

Cited in this article [1]

[35]

Yang

, Pan

, Wu

, et al. Antimicrobial resistance in clinical Ureaplasma spp. and Mycoplasma hominis and structural mechanisms underlying quinolone resistance[J]. Antimicrob Agents Chemother, 2020, 64(6): e02560-19. PMCID: PMC7269463. DOI: 10.1128/AAC.02560-19 .

https://www.ncbi.nlm.nih.gov/pubmed/32229497

Cited in this article [1]

[36]

Waites

, Crabb

, Xiao

, et al. In vitro activities of eravacycline and other antimicrobial agents against human mycoplasmas and ureaplasmas[J]. Antimicrob Agents Chemother, 2020, 64(8): e00698-20. PMCID: PMC7526834. DOI: 10.1128/AAC.00698-20 .

https://www.ncbi.nlm.nih.gov/pubmed/32513794

Cited in this article [1]

[37]	Guo F, Tang Y, Zhang W, et al. DnaJ, a promising vaccine candidate against Ureaplasma urealyticum infection[J]. Appl Microbiol Biotechnol, 2022, 106(22): 7643-7659. PMCID: PMC9589543. DOI: 10.1007/s00253-022-12230-4 . https://www.ncbi.nlm.nih.gov/pubmed/36269329 Cited in this article [1]

[38]	Fleming D, Patel R. Flurofamide prevention and treatment of Ureaplasma-induced hyperammonemia[J]. Microbiol Spectr, 2022, 10(5): e0192722. PMCID: PMC9602998. DOI: 10.1128/spectrum.01927-22 . https://www.ncbi.nlm.nih.gov/pubmed/35993783 Cited in this article [1]

[39]

Biernat-Sudolska

, Rojek-Zakrzewska

, Bilska-Wilkosz

. In-vitro activity of lipoic acid against Ureaplasma urealyticum and Ureaplasma parvum isolated from women with infections of the urogenital tract. A pilot study[J]. Acta Biochim Pol, 2020, 67(4): 623-628. DOI: 10.18388/abp.2020_5413 .

https://www.ncbi.nlm.nih.gov/pubmed/33332062

Cited in this article [1]

[40]

Chen

, Zhang

, Zeng

, et al. Subtractive genomics and comparative metabolic pathways profiling revealed novel drug targets in Ureaplasma urealyticum [J]. Front Microbiol, 2024, 15: 1484423. PMCID: PMC11557531. DOI: 10.3389/fmicb.2024.1484423 .

https://www.ncbi.nlm.nih.gov/pubmed/39539704

Cited in this article [1]